181 research outputs found
Mukopolisakkaridoz hastalarındaki otolarengolojik bulgular
Bu derleme makalede MPS hastalarındaki otolarengolojik sorunları raporladık. Mukopolisakkaridozlar (MPS'ler) her biri mukopolisakkaritlerin parçalanmasında rol alan ve şimdilerde glikozaminoglikanlar denilen (GAG'ler) kalıtsal bir enzim eksikliği nedeniyle oluşan bir lizozom depo hastalıkları grubudur. Mukopolisakkaridozlar, mukopolisakkaridoz tip 1-VII diye bilinen 7 metabolizma hastalığı grubunu oluştururlar. Grupların tümünde klinik ve otolaringolojik belirtiler görülür. Mukopolisakkaridoz hastalarında sık görülen otolarengolojik bulgular olarak üst hava yolu obstrüksiyonu, obstrüktif uyku apnesi, ağız açmanın kısıtlanması, orta kulak efüzyonu, işitme ve soluma sorunları vb. bildirilmektedir. KBB uzmanları arasında MPS'ler konusunda farkındalığın artırılması çocuk doktorundan ziyade bir KBB uzmanına giden MPS'den kuşkulanılan hastalar için yaşam kurtarıcı bir çaba olacaktır. Mukopolisakkaridoz hastalarında kısa boyun nedeniyle trakeotomi yapmak zorlaşabilir. Ağız açmanın kısıtlanması nedeniyle tonsillektomi ve adsenoidektomi ameliyatlarından önce hastalar dikkatle değerlendirilmelidir. Anesteziden önce hava yolu sorunları değerlendirilmelidir. Tüm KBB uzmanlarının bu sorunların farkınnda olmaları konusunda dikkati çekilmelidir.In this review paper, we reported otolaryngological problems in patients with mucopolysaccharidoses (MPSs). Mucopolysaccharidoses are a group of lysosomal storage diseases, each of which is produced by an inherited deficiency of an enzyme involved in the degradation of acid mucopolysaccharides, now called glycosaminoglycans (GAGs). The mucopolysaccharidoses consist of a group of 7 metabolic disorders, known as mucopolysaccharidoses types I-VII. In all groups, there are clinical and otolaryngological manifestations. In MPS patients, upper airway obstruction, obstructive sleep apnea, restriction of mouth opening, middle ear effusion, hearing and breathing problems, etc. are reported as common otolaryngological findings. Increasing awareness of MPS's among ENT doctors will be a life saving attempt for MPS suspected patients who admit an ENT doctor rather than a pediatrician. In MPS patients, tracheotomy may be difficult due to short neck. Due to mouth opening restriction, patients should be evaluated carefully before tonsillectomy and adenoidectomy operations. Airway problems must be evaluated before anesthesia. All ENT doctors should be noticed to be aware of these problems
Nasolacrimal duct obstruction: the relationship with nasal allergy
Abstract
Nasolacrimal duct obstruction (NLDO) is a common event in clinical practice. The authors, all members of the Italian Society of Rhinology, analysed 100 cases from different ENT Departments. The causes of NLDO, according to the etiology, can be divided into two classes: idiopathic primary acquired nasolacrimal duct obstruction and secondary. The aim of the study was to describe an association between the sign and symptoms of chronic rhinosinusitis and a complaint of epiphora
Phototherapy for allergic rhinitis: a prospective, randomized, single-blind, placebo-controlled study
Abstract: Phototherapy has a profound immunosuppressive effect, and phototherapeutic methods using both ultraviolet (UV) and visible light are therefore widely used for the therapy of various inflammatory skin diseases. It is also proposed that phototherapy, using a combination of UV-A (25%), UV-B (5%) and visible light (70%), may represent a therapeutic alternative in patients with allergic rhinitis. Seventy nine patients were randomly assigned to receive either a combination of UV-A (25%), UV-B (5%) and visible light (70%), in the phototherapy group, or low-intensity visible light, in the control group. The efficacy of treatment was assessed by means of total nasal symptom score before treatment and 1 month after the end of treatment. Total nasal scores decreased in both groups but the decrease was highly significant in the active treatment group when compared with the placebo (p < 0.001). This study demonstrates that phototherapy may be an effective modality in the treatment of allergic rhinitis especially in cases of which commonly used drugs either are contraindicated and/or have insufficient efficacy
Facial mask for prevention of allergic rhinitis symptoms
ObjectivesWe reviewed the role of facial masks in preventing allergic rhinitis (AR) symptoms.MethodsThe literature survey was performed in PubMed, EBSCO, UpToDate, and Proquest Central databases of Kırıkkale University and Google and Google Scholar databases.ResultsAeroallergens are microscopic airborne particles that trigger AR symptoms. In sensitive people, the type 1 hypersensitivity reaction against these allergens occurs when these microparticles enter the nasal mucosa via inhalation. Pollens, molds, dust mites, and animal dander are only some of the allergens suspected of contributing to AR symptoms. The treatment guidelines for AR extensively encompass allergy avoidance and environmental management as the first-line treatment. It is recommended that those who experience seasonal symptoms try to avoid their triggers whenever possible. While medical masks filter out particles larger than 3 μm, FFP2 masks are effective against particles as small as 0.004 μm. Since both mask types are effective in filtering pollen larger than 5 μm in size, they can be used to prevent pollen exposure. The “antiviral protection” provided by medical and FFP2 masks to hospital employees is roughly equivalent. Thus, both should be effective against direct local (eye) or indirect inhaled (nose, bronchial) pollen exposure. For the masks to do their job, they need to fit correctly.ConclusionFace mask affects AR patients' quality of life and reduces AR symptoms' severity
The effects of spirulina on allergic rhinitis
Abstract The prevalence of allergic rhinitis is increasing globally due to various causes. It affects the quality life of a large group of people in all around the world. Allergic rhinitis still remains inadequately controlled with present medical means. The need of continuous medical therapy makes individuals anxious about the side effects of the drugs. So there is a need for an alternative strategy. Effects of spirulina, tinospora cordifolia and butterbur were investigated recently on allergic rhinitis in just very few investigations. Spirulina represents a blue-green alga that is produced and commercialized as a dietary supplement for modulating immune functions, as well as ameliorating a variety of diseases. This double blind, placebo controlled study, evaluated the effectiveness and tolerability of spirulina for treating patients with allergic rhinitis. Spirulina consumption significantly improved the symptoms and physical findings compared with placebo (P \ 0.001***) including nasal discharge, sneezing, nasal congestion and itching. Spirulina is clinically effective on allergic rhinitis when compared with placebo. Further studies should be performed in order to clarify the mechanism of this effect
ORIGINAL RESEARCH-FACIAL PLASTIC AND RECONSTRUCTIVE SURGERY Augmentation mentoplasty with osteocartilaginous nasal graft
The Nose as a Route for Therapy: Part 1. Pharmacotherapy
This article reviews nasal structure and function in the light of intranasal pharmacotherapy. The nose provides an accessible, fast route for local treatment of nose and sinus diseases, with lower doses than are necessary systemically and few adverse effects. It can also be used for other medications as it has sufficient surface area protected from local damage by mucociliary clearance, absence of digestive enzymes, responsive blood flow, and provides a rapid route to the central nervous system.Peer reviewe
Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review
Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing
the EAACI Guidelines for Allergen Immunotherapy (AIT) for the Management of Allergic Rhinoconjunctivitis.
We seek to critically assess the effectiveness, cost-effectiveness and safety of AIT in the management of allergic
rhinoconjunctivitis.
Methods: We will undertake a systematic review, which will involve searching international biomedical databases
for published, in progress and unpublished evidence. Studies will be independently screened against pre-defined
eligibility criteria and critically appraised using established instruments. Data will be descriptively and, if possible and
appropriate, quantitatively synthesised.
Conclusion: The findings from this review will be used to inform the development of recommendations for EAACI’s
Guidelines on AIT
Behavioural patterns in allergic rhinitis medication in Europe : A study using MASK-air(R) real-world data
Background Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data. Methods We analysed 2015-2020 MASK-air(R) European data. We compared days under no medication, monotherapy and co-medication using the visual analogue scale (VAS) levels for overall allergic symptoms ('VAS Global Symptoms') and impact of AR on work. We assessed the monthly use of different medication schemes, performing separate analyses by region (defined geographically or by Google Trends patterns). We estimated the average number of different drugs reported per patient within 1 year. Results We analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy and 38,315 (17.3%) under co-medication. The median 'VAS Global Symptoms' was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p < .001). Medication use peaked during the spring, with similar patterns across different European regions (defined geographically or by Google Trends). Oral H-1-antihistamines were the most common medication in single and co-medication. Each patient reported using an annual average of 2.7 drugs, with 80% reporting two or more. Conclusions Allergic rhinitis medication patterns are similar across European regions. One third of treatment days involved co-medication. These findings suggest that patients treat themselves according to their symptoms (irrespective of how they understand AR) and that co-medication use is driven by symptom severity.Peer reviewe
- …